

ESOPHAGEAL CANCER CANCER DE L'ŒSOPHAGE

MAY 8 AND 9, 2009



SESSION 1 | Chair: André Duranceau

- 8:00 Welcome and introduction
Pasquale Ferraro (Montréal, Québec)
Chair, Thoracic Surgery Division
- 8:30 Epidemiology and pathogenesis of esophageal cancer in 2009
A.H. Hölscher (Cologne, Germany)
- 8:45 Esophagogastric cancer services in the United Kingdom: from nihilism to specialism
M. Griffin (Newcastle-Upon-Tyne, UK)
- 9:00 Changes in practice in the last three decades
M.K. Ferguson (Chicago, IL)
- 9:15 A uniform database for management and reporting
T.W. Rice (Cleveland, OH)
- 9:30 Panel Discussion
- Coffee

SESSION 2 | Chair: Gilles Beauchamp

- 10:15 Radiologic evaluation of esophageal cancer
L. Samson (Montréal, Québec)
- 10:30 Endoscopy and EUS
M. Liberman (Montréal, Québec)
- 10:45 Prospective assessment of PET staging
J.J. van Lanschot (Amsterdam)
- 11:00 Sentinel node assessment in esophageal cancer
M. Griffin (Newcastle-Upon-Tyne, UK)
- 11:15 Panel Discussion
- Lunch

SESSION 3 | Chair: Pasquale Ferraro

- 1:30 The new TNM staging
T.W. Rice (Cleveland, OH)
- 1:45 Methodology of lymph node assessment
G.G. Jamieson (Adelaide, Australia)
- 2:00 Lymph node resection radicality vs numbers
A.F. Hölscher (Cologne, Germany)
- 2:15 Genetics and molecular staging
J.J. van Lanschot (Amsterdam)
- 2:30 Panel Discussion
- Coffee

SESSION 4 | Chair: Éric Fréchette

- 3:15 Chemotherapy alone as definitive treatment
J.P. Ayoub (Montréal, Québec)
- 3:30 Pros and cons of neoadjuvant treatment
J.J. van Lanschot (Amsterdam)
- 3:45 The complete endoscopic responder
A.F. Hölscher (Cologne, Germany)
- 4:00 Is there an indication for restaging after neoadjuvant therapy?
J. Martin (Montréal, Québec)
- 4:15 Panel Discussion



Thoracic Surgery Division

André Duranceau
Pasquale Ferraro
Jocelyne Martin
Moishe Liberman

Tel. : 514-890-8000, ext.: 26253
e-mail: andre.duranceau@umontreal.ca

THORACIC SURGERY
Research Foundation
of Montreal

SESSION 5 | Chair: Jocelyne Martin

- 8:30 The esophageal remnant after gastric interposition
A. Duranceau (Montréal, Québec)
- 8:45 Quality of life after esophagectomy
D. Ouellette (Montréal, Québec)
- 9:00 Ischemic conditioning of the stomach for esophageal replacement
A.F. Hölscher (Cologne, Germany)
- 9:15 Standardization of perioperative clinical pathways
D. Maziak (Ottawa, Ontario)
- 9:30 Panel Discussion
- Coffee

SESSION 6 | Chair: Rosaire Vaillancourt


- 10:15 Risk profiling in esophageal cancer patients
M. Ferguson (Chicago, IL)
- 10:30 The Amsterdam/Rotterdam risk assessment model
J.J. van Lanschot (Amsterdam)
- 10:45 High grade dysplasia and esophageal cancer: role of mucosal resection
M. Liberman (Montréal, Québec)
- 11:00 Early esophageal cancer: role of surgery
T.W. Rice (Cleveland, OH)
- 11:15 Panel Discussion
- Lunch

SESSION 7 | Chair: Moishe Liberman

- 1:30 Trans hiatal vs trans thoracic resection
J.J. van Lanschot (Amsterdam)
- 1:45 Minimally invasive esophagectomy
M. Ferguson (Chicago, IL)
- 2:00 Radical esophagectomy for cancer
M. Griffin (Newcastle-Upon-Tyne, UK)
- 2:15 Reporting mortality after an esophagectomy
G.G. Jamieson (Adelaide, Australia)
- 2:30 Panel Discussion
- Coffee

SESSION 8 | Chair: Jocelyn Grégoire

- 3:15 Palliating esophageal cancer prosthesis vs radio and/or chemotherapy
G. Beauchamp (Montréal, Québec)
- 3:30 Reflux prevention after esophagectomy
G.G. Jamieson (Adelaide, Australia)
- 3:45 Management of anastomotic and mediastinal leaks
M. Griffin (Newcastle-Upon-Tyne, UK)
- 4:00 Managing the failed reconstruction
M. Ferguson (Chicago, IL)
- 4:15 Panel Discussion
- Closure



The official language of the Symposium is English

Approved for C.M.E. credits
Université de Montréal